OP
NBIX icon

ORG Partners’s Neurocrine Biosciences NBIX Stock Holding History

ORG Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$27.1K Buy
191
+32
+20% +$4.64K ﹤0.01% 717
2025
Q3 		$22.3K Buy
159
+91
+134% +$12.3K ﹤0.01% 770
2025
Q2 		$8.7K Buy
68
+63
+1,260% +$7.22K ﹤0.01% 933
2025
Q1 		$535 Buy
+5
New +$633 ﹤0.01% 1267

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ORG Partners's NBIX Position: Q4 2025 in Review

ORG Partners increased its Neurocrine Biosciences (NBIX) stake by 20% in Q4 2025, buying an estimated $4.64K and bringing the position to 191 shares worth $27.1K. The position accounts for ﹤0.01% of the portfolio, ranked #717.

ORG Partners first reported a position in NBIX in Q1 2025 and has held it in 4 quarters since. 732 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • ORG Partners held 191 shares of Neurocrine Biosciences worth $27.1K as of Q4 2025.
  • ORG Partners bought 32 Neurocrine Biosciences shares in Q4 2025, an estimated $4.64K.
  • Neurocrine Biosciences made up ﹤0.01% of ORG Partners's portfolio in Q4 2025, its #717 holding.
  • ORG Partners first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 4 quarters since.
  • 732 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.